- 日
- 関
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/12/12 21:08:11」(JST)
[Wiki en表示]
Enprostil
|
| Systematic (IUPAC) name |
|
methyl 7-[(1S,2S,3S)-3-hydroxy-2-[(3R)-3-hydroxy-4-phenoxybut-1-enyl]-5-oxocyclopentyl]hepta-4,5-dienoate
|
| Clinical data |
| AHFS/Drugs.com |
International Drug Names |
| Identifiers |
| CAS Number |
73121-56-9 Y |
| ATC code |
A02BB02 |
| PubChem |
CID: 51744 |
| UNII |
J4IP5Z9DAU Y |
| KEGG |
D01891 Y |
| Chemical data |
| Formula |
C23H28O6 |
| Molecular mass |
400.46 g/mol |
| Y (what is this?) (verify) |
Enprostil is a synthetic prostaglandin designed to resemble dinoprostone. Enprostil was found to be a highly potent inhibitor of gastric HCl secretion.[1]
References
- ^ Roszkowski, AP; Garay, GL; Baker, S; Schuler, M; Carter, H (1986). "Gastric antisecretory and antiulcer properties of enprostil, (+/−)-11 alpha, 15 alpha-dihydroxy-16-phenoxy-17,18,19,20-tetranor-9-oxoprosta-4,5,13(t)-trienoic acid methyl ester". The Journal of Pharmacology and Experimental Therapeutics 239 (2): 382–9. PMID 3095537.
External links
- Toshina, K.; Hirata, I.; Maemura, K.; Sasaki, S.; Murano, M.; Nitta, M.; Yamauchi, H.; Nishikawa, T.; et al. (2000). "Enprostil, a Prostaglandin-E2 Analogue, Inhibits Interleukin-8 Production of Human Colonic Epithelial Cell Lines". Scandinavian Journal of Immunology 52 (6): 570–5. doi:10.1046/j.1365-3083.2000.00815.x. PMID 11119262.
- Tari, Akira; Hamada, Masanori; Kamiyasu, Toshiki; Sumii, Koji; Haruma, Ken; Inoue, Masaki; Kishimoto, Shinya; Kajiyama, Goro; Walsh, John H. (1997). "Effect of enprostil on omeprazole-induced hypergastrinemia and inhibition of gastric acid secretion in peptic ulcer patients". Digestive Diseases and Sciences 42 (8): 1741–6. doi:10.1023/A:1018825902055. PMID 9286243.
- Ching, C. K.; Lam, S. K. (1995). "A comparison of two prostaglandin analogues (enprostil vs misoprostol) in the treatment of acute duodenal ulcer disease". Journal of Gastroenterology 30 (5): 607–14. doi:10.1007/BF02367786. PMID 8574332.
|
Drugs for peptic ulcer and GERD/GORD (A02B)
|
|
| H2 antagonists ("-tidine") |
- Cimetidine
- Famotidine
- Lafutidine
- Loxtidine
- Niperotidine
- Nizatidine
- Ranitidine
- Roxatidine
|
|
| Prostaglandins (E)/analogues ("-prost-") |
|
|
| Proton-pump inhibitors ("-prazole") |
- Dexlansoprazole
- Esomeprazole
- Ilaprazole
- Lansoprazole
- Omeprazole
- Pantoprazole
- Picoprazole
- Rabeprazole
- Tenatoprazole
- Timoprazole
|
|
| Potassium-competitive acid blockers ("-prazan") |
- Linaprazan
- Revaprazan
- Soraprazan
- Vonoprazan
|
|
| Other |
- Acetoxolone
- Alginic acid
- Arbaclofen placarbil
- Carbenoxolone
- Cetraxate
- Gefarnate
- Lesogaberan
- Pirenzepine
- Proglumide
- Rebamipide
- Sucralfate
- Sulglicotide
- Telenzepine
- Teprenone
- Troxipide
- Zolimidine
|
|
| Combinations |
- Bismuth subcitrate/metronidazole/tetracycline
|
|
- See also: Helicobacter pylori eradication protocols
|
|
|
Index of digestion
|
|
| Description |
- Anatomy
- Physiology
- Development
|
|
| Disease |
- Congenital
- Neoplasms and cancer
- Inflammatory bowel disease
- Gluten sensitivity
- Other
- Symptoms and signs
- Blood tests
|
|
| Treatment |
- Procedures
- Drugs
- anabolic steroids
- antacids
- diarrhoea and infection
- bile and liver
- functional gastrointestinal disorders
- laxatives
- peptic ulcer and reflux
- nausea and vomiting
- other
- Surgery
|
|
|
|
Eicosanoids
|
|
| Precursor |
|
|
| Prostanoids |
| Prostaglandins (PG) |
| Precursor |
|
|
| Active |
| D/J |
|
|
| E/F |
|
|
| I |
- I2 (Prostacyclin/Epoprostenol):
|
|
|
|
| Thromboxanes (TX) |
|
|
|
| Leukotrienes (LT) |
| Precursor |
- Arachidonic acid 5-hydroperoxide
|
|
| Initial |
|
|
| SRS-A |
|
|
|
| Eoxins (EX) |
| Precursor |
- Arachidonic acid 15-hydroperoxide
|
|
| Eoxins |
|
|
|
| Nonclassic |
- Lipoxins (LX) (A4, B4)
- Virodhamine
|
|
| By function |
- vasoconstriction
- vasodilation
- platelets: induce
- inhibit
- leukocytes: induce
- inhibit
- labor stimulation:
- PGE2 (Dinoprostone)
- PGF2α (Dinoprost)
|
|
|
Index of inborn errors of metabolism
|
|
| Description |
- Metabolism
- Enzymes and pathways: citric acid cycle
- pentose phosphate
- glycoproteins
- glycosaminoglycans
- phospholipid
- cholesterol and steroid
- sphingolipids
- eicosanoids
- amino acid
- urea cycle
- nucleotide
|
|
| Disorders |
- Citric acid cycle and electron transport chain
- Glycoprotein
- Proteoglycan
- Fatty-acid
- Phospholipid
- Cholesterol and steroid
- Eicosanoid
- Amino acid
- Purine-pyrimidine
- Heme metabolism
- Symptoms and signs
|
|
| Treatment |
|
|
Index of biochemical families
|
|
| Carbohydrates |
- Alcohols
- Glycoproteins
- Glycosides
|
|
| Lipids |
- Eicosanoids
- Fatty acids
- Glycerides
- Phospholipids
- Sphingolipids
- Steroids
|
|
| Nucleic acids |
|
|
| Proteins |
|
|
| Other |
|
|
|
|
Prostanoid signaling
|
|
Receptor
(ligands) |
|
|
Enzyme
(inhibitors) |
| Cyclooxygenase |
|
|
| PGD2 synthase |
- Retinoids
- Selenium (selenium tetrachloride, sodium selenite, selenium disulfide)
|
|
| PGE synthase |
HQL-79
|
|
| PGF synthase |
Bimatoprost
|
|
| PGI2 synthase |
Tranylcypromine
|
|
| TXA synthase |
- Camonagrel
- Dazmegrel
- Dazoxiben
- Furegrelate
- Isbogrel
- Midazogrel
- Nafagrel
- Nicogrelate
- Ozagrel
- Picotamide
- Pirmagrel
- Ridogrel
- Rolafagrel
- Samixogrel
- Terbogrel
- U63557A
|
|
|
| Others |
- Precursors: Linoleic acid
- γ-Linolenic acid (gamolenic acid)
- Dihomo-γ-linolenic acid
- Diacylglycerol
- Arachidonic acid
- Prostaglandin G2
- Prostaglandin H2
|
|
|
See also: Leukotrienergics
|
|
English Journal
- [Efficacy of prostaglandin derivatives and mucoprotective drugs in treatment and prevention for NSAIDs-induced ulcer].
- Fujikawa Y, Watanabe T, Tominaga K, Fujiwara Y, Sato H, Arakawa T.SourceDepartment of Gastroenterology, Osaka City University Graduate School of Medicine.
- Nihon rinsho. Japanese journal of clinical medicine.Nihon Rinsho.2011 Jun;69(6):1039-43.
- Deficiency of prostaglandins (PGs) by non-steroidal anti-inflammatory drugs (NSAIDs) causes a loss of gastroduodenal mucosal integrity, leading to development of ulceration. PG derivatives such as misoprostol and enprostil have been proven effective in prevention and treatment of NSAIDs-induced gast
- PMID 21688624
- Properties of Rikkunshi-to (TJ-43)-induced relaxation of rat gastric fundus smooth muscles.
- Kito Y, Suzuki H.SourceDept. of Physiology, Nagoya City Univ. Medical School, Mizuho-ku, Nagoya, Japan. y.kito@med.nagoya-cu.ac.jp
- American journal of physiology. Gastrointestinal and liver physiology.Am J Physiol Gastrointest Liver Physiol.2010 May;298(5):G755-63. Epub 2010 Feb 18.
- The relaxant effects of Rikkunshi-to (TJ-43), a gastroprotective herbal medicine, on rat gastric fundus were investigated. Experiments were carried out using standard tension and intracellular microelectrode recording techniques. During contraction induced by enprostil (0.5 microM), a prostaglandin
- PMID 20167876
Japanese Journal
- NSAIDs潰瘍の予防・治療における抗潰瘍薬の位置づけ プロスタグランジン製剤・防御因子増強薬 (特集 NSAIDs潰瘍--最新の予防・治療) -- (NSAIDs潰瘍の予防・治療戦略)
- エンプロスチルの胃潰瘍における微小血液循環への影響 : Levovist^<TM> 造影下 Flash Echo Imaging による検討
- 松村 俊二,畠 二郎,春間 賢,原 睦展,中村 顕治朗,岡信 秀治,二神 浩司,吉田 成人,楠 裕明,茶山 一彰
- Journal of medical ultrasonics = 超音波医学 28(3), J581, 2001-04-15
- NAID 10012356448
- Enprostil, a prostaglandin-E(2) analogue, inhibits interleukin-8 production of human colonic epithelial cell lines
Related Links
- Enprostil is a synthetic prostaglandin designed to resemble dinoprostone. Enprostil was found to be a highly potent inhibitor of gastric HCl secretion. [edit] References. ^ Roszkowski, AP; Garay, GL; Baker, S; Schuler, M; Carter, H (1986).
Related Pictures
★リンクテーブル★
[★]
- 英
- enprostil
- 商
- カムリード
-
構造
作用機序
薬理作用
動態
適応
注意
禁忌
- 子宮収縮作用があるらしい
副作用
相互作用
[★]
- 英
- 関
H2 blocker, PPI抵抗性潰瘍に併用できる
PGE誘導体 プロスタグランジン製剤
エンブロスチル
粘膜保護
組織修復
抗ドパミン作用
禁忌
下痢、妊婦
